Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 in breast cancer receiving myelotoxic chemotherapy
NCT01648322Phase 2Completed
- Sponsor
- Evive Biotech
- Start
- Jun 2012
- Primary completion
- Dec 2014
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in neutropenia, sponsored by Evive Biotech. Started Jun 2012; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT01648322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648322.